Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study).
Dilek Yilmaz CiftdoganYıldız Ekemen-KeleşAdem KarbuzBenhur Sirvan CetinSefika Elmas BozdemirEda Kepenekli KadayifciOzge Metin AkcanArife OzerTugba EratMurat SutcuAyse BuyukcamNursen BeletEmine Hafize ErdenizNazan DalgıçSelda Hancerli TorunSelim OncelZerrin OrbakOzden TurelZeynep Gokce Gayretli AydinOmer KilicAysun YahşiAhu Kara AksayZeynep ErgencMey Talip PetmezciMehmet Burhan OflazRemzi SarikayaGülcin Otar YenerSeval OzenDoruk GulGazi ArslanSoner Sertan KaraDemet DemirkolPinar Yazici OzkayaYilmaz YozgatCelal VaranManolya KaraGül ArgaNurhayat YakutAhmet Osman KilicOzlem CakiciMehmet KucukÖzge KabaHatice Karaoglu AsrakBurcu Bursal DuramazTahir DalkiranAyse Berna AnilMehmet TurgutBulent KarapinarAyper SomerFerhan ElmaliEner Cagri DinleyiciErgin CiftciAtes KaraPublished in: Journal of paediatrics and child health (2022)
The clinical spectrum of MIS-C is broad, but clinicians should consider MIS-C in the differential diagnosis when persistent fever, fatigue and gastrointestinal symptoms are prominent. Most patients diagnosed with MIS-C were previously healthy. Immunomodulatory treatment and supportive intensive care are important in the management of cases with MIS-C. Glucocorticoids and intravenous immunoglobulins are the most common immunomodulatory treatment options for MIS-C. Prompt diagnosis and prompt treatment are essential for optimal management.